- Datum01.09.2025
- Uhrzeit08:00 - 09:00 Uhr
- Veranstalter
XTB
Stefan Salomon
Moderator
Immuneering Corp Aktie
Verkaufen
Kaufen
Immuneering Corp Chart
Immuneering Corp Realtime-Kurs
| Handelsplatz | Kurs | +/- (%) | +/- (abs) | Vortag | Zeit | Aktionen |
|---|---|---|---|---|---|---|
| Nasdaq | VK | |||||
| Nasdaq Basic | VK | |||||
| Cboe BZX | VK |
Passende Produkte
| WKN | Long/Short | KO | Hebel | Laufzeit | Bid | Ask |
|---|
Keine Ergebnisse gefunden
Wertentwicklung (Nasdaq)
2,68 %
Intraday
17,59 %
1 Woche
56,25 %
1 Monat
161,36 %
Seit Jahresbeginn
395,69 %
1 Jahr
-4,17 %
3 Jahre
Passender Service zu Immuneering Corp
Webinar zu Immuneering Corp
Kursinformationen (Nasdaq)
- Tagestief / Hoch ($)-
- 52W-Tief / Hoch ($)1,100-6,180
- Jahrestief / Hoch ($)1,100-6,180
- Schlusskurs (Vortag)
- Eröffnungskurs
- Volumen Intraday
Wichtigste Eigenschaften
Dividenden von Immuneering Corp
Keine Dividenden verfügbar
Termine von Immuneering Corp
Keine aktuellen Termine
Beschreibung
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts. Immuneering Corporation was a former subsidiary of Teva Pharmaceutical Industries Limited.
